Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3645 - Prognostic significance of neutrophil to lymphocyte ratio (NLR) in patients (pts) with resectable gastric/gastroesophageal junction (GOJ) adenocarcinoma undergoing perioperative chemotherapy


08 Oct 2016


Poster Display


Zena Salih


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


Z. Salih1, A.M. Conway2, G. Papaxoinis2, A. Patrao2, K. Fletcher2, R. Noble2, V. Owen-Holt2, W. Mansoor2

Author affiliations

  • 1 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 2 Medical Oncology, The Christie NHS Foundation Trust, Manchester/GB


Abstract 3645


No validated preoperative prognostic markers exist for pts with resectable gastric/GOJ adenocarcinoma (AC). There is evidence that NLR and platelet-to-lymphocyte ratio (PLR) predict outcomes in different types of malignancies. We aimed to explore the prognostic significance of NLR in pts with resectable gastric/GOJ AC undergoing perioperative chemotherapy.


In this retrospective cohort study, baseline neutrophil, lymphocyte and platelet blood count levels were recorded for all pts with resectable gastric/GOJ AC commenced on neoadjuvant ECX-based chemotherapy (Jul'09-Dec'14). The prognostic significance of baseline characteristics and blood count levels on overall survival (OS) and tumour resectability was tested by Cox-regression analysis. All comparisons were two-sided with level of significance p 


Of 368 pts included, 95 pts (26%) had gastric and 273 (74%) had GOJ primaries. ECOG Performance status (PS) was 0 in 133 (36%) and 1-2 in 235 pts (64%); 294 pts (80%) had curative surgery. After a median follow-up of 42 months (mo) (range 0.5-77) 209 (57%) pts were deceased. Increasing NLR associated with shorter OS (HR = 1.13, 95%CI = 1.06-1.19, p 


NLR is highly prognostic in pts with resectable gastric/GOJ AC undergoing neoadjuvant ECX chemotherapy. We propose a baseline prognostic model that might inform prognosis and aid stratification of pts in clinical trials.

Clinical trial identification


Legal entity responsible for the study

The Christie NHS Foundation Trust


The Christie NHS Foundation Trust


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings